MAPK3 and malignant colon neoplasm: NKA increased the viability and proliferation of colon cancer cells and the phosphorylation of extracellular-signal-regulated kinase 1/2 levels in interferon-α/β-treated colon cancer cells, whereas NK-2R antagonists reduced the proliferation of these cells [143].